Bakterial'nyy vaginoz i beremennost' (obzor literatury)

Cite item

Full Text


About the authors

A M Savicheva

E V Shipitsyna


  1. Olmsted SS, Meyn LA, Rohan LC, Hillier SL. Glycosidase and proteinase activity of anaerobic gram-negative bacteria isolated from women with bacterial vaginosis. Sex Transm Dis 2003; 30 (3): 257-61.
  2. Koumans EH, Sternberg M, Bruce C et al. The prevalence of bacterial vaginosis in the United States, 2001-2004: associations with symptoms, sexual behaviors, and reproductive health. Sex Transm Dis 2007; 34: 864-9.
  3. Wilson J. Managing recurrent bacterial vaginosis. Sex Transm Infect 2004; 80 (1): 8-11.
  4. Bradshaw CS, Morton AN, Hocking J et al. High recurrence rates of bacterial vaginosis over the course of 12 months after oral metronidazole therapy and factors associated with recurrence. J Infect Dis 2006; 193:1478-86.
  5. Spiegel CA. Bacterial vaginosis. Rev Med Microbiol 2002; 13: 43-51.
  6. Verstraelen H, Verhelst R, Claeys G et al. Culture-independent analysis of vaginal microflora: the unrecognized association of Atopobium vaginae with bacterial vaginosis. Am J Obstet Gynecol 2004; 191: 1130-2.
  7. Fredricks DN, Fiedler TL, Marrazzo JM. Molecular identification of bacteria associated with bacterial vaginosis. N Engl J Med 2005; 353: 1899-911.
  8. Zozaya-Hinchliffe M, Martin DH, Ferris MJ. Prevalence and abundance of uncultivated Megasphaera-like bacteria in the human vaginal environment. Appl Environ Microbiol 2008; 74: 1656-9.
  9. Schwebke JR, Weiss HL. Interrelationships of bacterial vaginosis and cervical inflammation. Sex Transm Dis 2002; 29: 59-64.
  10. Wiesenfeld HC, Hillier SL, Krohn MA et al. Bacterial vaginosis is a strong predictor of Neisseria gonorrhoeae and Chlamydia trachomatis infection. Clin Infect Dis 2003; 36: 663-8.
  11. Allsworth JE, Peipert JF. Severity of bacterial vaginosis and the risk of sexually transmitted infection. Am J Obstet Gynecol 2011; 205 (2): 113.e1-6.
  12. Cherpes TL, Meyn LA, Krohn MA et al. Association between acquisition of herpes simplex virus type 2 in women and bacterial vaginosis. Clin Infect Dis 2003; 37: 319-25.
  13. Myer L, Kuhn L, Stein ZA et al. Intravaginal practices, bacterial vaginosis, and women's susceptibility to HIV infection: epidemiological evidence and biological mechanisms. Lancet Infect Dis 2005; 5: 786-94.
  14. Sweet RL. Role of bacterial vaginosis in pelvic inflammatory disease. Clin Infect Dis 1995; 20 (Suppl. 2): S271-5.
  15. Hillier SL, Kiviat NB, Hawes SE et al. Role of bacterial vaginosis-associated microorganisms in endometritis. Am J Obstet Gynecol 1996; 175: 435-41.
  16. Wiesenfeld H, Hillier S, Krohn M et al. Lower genital tract infection and endometritis: Insight into subclinical pelvic inflammatory disease. Obstet Gynecol 2002; 100: 456-63.
  17. Haggerty CL, Hillier SL, Bass DC, Ness RB. Bacterial vaginosis and anaerobic bacteria are associated with endometritis. Clin Infect Dis 2004; 39: 990-5.
  18. Ralph SG, Rutherford AJ, Wilson JD. Influence of bacterial vaginosis on conception and miscarriage in the first trimester: cohort study. BMJ 1999; 319: 220-3.
  19. McGregor JA, French JI, Jones W et al. Bacterial vaginosis is associated with prematurity and vaginal fluid mucinase and sialidase: results of a controlled trial of topical clindamycin cream. Am J Obstet Gynecol 1994; 170: 1048-59.
  20. Hay PE, Lamont RF, Taylor-Robinson D et al. Abnormal bacterial colonisation of the genital tract and subsequent preterm delivery and late miscarriage. BMJ 1994; 308: 295-8.
  21. Kurki T, Sivonen A, Renkonen OV et al. Bacterial vaginosis in early pregnancy and pregnancy outcome. Obstet Gynecol 1992; 80: 173-7.
  22. Lamont RF, Taylor-Robinson D, Newman M et al. Spontaneous early preterm labour associated with abnormal genital bacterial colonization. Br J Obstet Gynaecol 1986; 93: 804-10.
  23. Hillier SL, Nugent RP, Eschenbach DA et al. Association between bacterial vaginosis and preterm delivery of a low-birth-weight infant. The Vaginal Infections and Prematurity Study Group. N Engl J Med 1995; 333: 1737-42.
  24. Silver HM, Sperling RS, St Clair PJ, Gibbs RS. Evidence relating bacterial vaginosis to intraamniotic infection. Am J Obstet Gynecol 1989; 161: 808-12.
  25. Hillier SL, Martius J, Krohn M et al. A case-control study of chorioamnionic infection and histologic chorioamnionitis in prematurity. N Engl J Med 1988; 319: 972-8.
  26. Martius J, Eschenbach DA. The role of bacterial vaginosis as a cause of amniotic fluid infection, chorioamnionitis and prematurity - a review. Arch Gynecol Obstet 1990; 247: 1-13.
  27. Watts DH, Krohn MA, Hillier SL, Eschenbach DA. Bacterial vaginosis as a risk factor for post-cesarean endometritis. Obstet Gynecol 1990; 75: 52-8.
  28. Korn AP, Bolan G, Padian N et al. Plasma cell endometritis in women with symptomatic bacterial vaginosis. Obstet Gynecol 1995; 85: 387-90.
  29. Khatamee MA, Sommers SC. Clinicopathologic diagnosis of mycoplasma endometritis. Int J Fertil 1989; 34: 52-5.
  30. Bennett BB, Clark P, Riley P et al. The association of asymptomatic bacterial vaginosis with upper genital tract infection. Prim Care Update Ob Gyns 1998; 5 (4): 150.
  31. Bhattacharjee B, Herrington CS, Sunderland D, Birley HD. Scanning electron microscopy of endometrial biopsies of patients with bacterial vaginosis shows morphology resembling mycoplasma/ureaplasma organisms. Sex Transm Infect 1999; 75: 202.
  32. Keelan JA, Blumenstein M, Helliwell RJ et al. Cytokines, prostaglandins and parturition-a review. Placenta 2003; (24 suppl. A): S33-S46.
  33. Cauci S, Thorsen P, Schendel DE et al. Determination of immunoglobulin A against Gardnerella vaginalis hemolysin, sialidase, and prolidase activities in vaginal fluid: implications for adverse pregnancy outcomes. J Clin Microbiol 2003; 41: 435-8.
  34. Macones GA, Parry S, Elkousy M et al. A polymorphism in the promoter region of TNF and bacterial vaginosis: preliminary evidence of gene-environment interaction in the etiology of spontaneous preterm birth. Am J Obstet Gynecol 2004; 190: 1504-8.
  35. Савичева А.М., Башмакова М.А., Красносельских Т.В. и др. Лабораторная диагностика бактериального вагиноза. СПб.: Н-Л, 2011.
  36. Workowski KA, Berman S. Centers for Disease Control and Prevention. Sexually transmitted diseases treatment guidelines, 2010. MMWR Recomm Rep 2010; 59: 1-110.
  37. Amsel R, Totten PA, Spiegel CA et al. Nonspecific vaginitis. Diagnostic criteria and microbial and epidemiologic associations. Am J Med 1983; 74: 14-22.
  38. Nugent RP, Krohn MA, Hillier SL. Reliability of diagnosing bacterial vaginosis is improved by a standardized method of gram stain interpretation. J Clin Microbiol 1991; 29: 297-301.
  39. Ison CA, Hay PE. Validation of a simplified grading of Gram stained vaginal smears for use in genitourinary medicine clinics. Sex Transm Infect 2002; 78 (6): 413-5.
  40. WHO. Sexually transmitted and other reproductive tract infections. A guide to essential practice. Annex 3. Laboratory tests for STI, 2005.
  41. Европейские стандарты диагностики и лечения заболеваний, передающихся половым путем. М.: Медицинская литература, 2004.
  42. Акушерство и гинекология - клинические рекомендации. Под ред. Г.М.Савельевой, В.Н.Серова, Г.Т.Сухих. 3-е изд. 2011.
  43. Goldstein EJ, Citron DM, Merriam CV et al. In vitro activities of Garenoxacin (BMS 284756) against 108 clinical isolates of Gardnerella vaginalis. Antimicrob Agents Chemother 2002; 46: 3995-6.
  44. Xiao JC, Xie LF, Fang SL et al. Symbiosis of Mycoplasma hominis in Trichomonas vaginalis may link metronidazole resistance in vitro. Parasitol Res 2006; 100: 123-30.
  45. Ferris MJ, Masztal A, Aldridge KE et al. Association of Atopobium vaginae, a recently described metronidazole resistant anaerobe, with bacterial vaginosis. BMC Infect Dis 2004; 4: 5.
  46. De Backer E, Dubreuil L, Brauman M et al. In vitro activity of secnidazole against Atopobium vaginae, an anaerobic pathogen involved in bacterial vaginosis. Clin Microbiol Infect 2010; 16: 470-2.
  47. Donders GG, Van Calsteren K, Bellen G et al. Predictive value for preterm birth of abnormal vaginal flora, bacterial vaginosis and aerobic vaginitis during the first trimester of pregnancy. BJOG 2009; 116: 1315-24.
  48. Workowski KA, Berman SM. Centers for Disease Control and Prevention sexually transmitted diseases treatment guidelines. Clin Infect Dis 2007; 44 (Suppl. 3): S73-6.
  49. Spiegel CA, Eschenbach DA, Amsel R, Holmes KK. Curved anaerobic bacteria in bacterial (nonspecific) vaginosis and their response to antimicrobial therapy. J Infect Dis 1983; 148: 817-22.
  50. Spiegel CA. Susceptibility of Mobiluncus species to 23 antimicrobial agents and 15 other compounds. Antimicrob Agents Chemother 1987; 31: 249-52.
  51. Barry AL, Thornsberry C, Jones RN. In vitro activity of a new macrolide, A-56268, compared with that of roxithromycin, erythromycin, and clindamycin. Antimicrob Agents Chemother 1987; 31: 343-5.
  52. Hillier S, Krohn MA, Watts DH et al. Microbiologic efficacy of intravaginal clindamycin cream for the treatment of bacterial vaginosis. Obstet Gynecol 1990; 76: 407-13.
  53. Zambrano D. Clindamycin in the treatment of obstetric and gynecologic infections: a review. Clin Ther 1991; 13: 58-80.
  54. Toma E, Fournier S, Poisson M et al. Clindamycin with primaquine for Pneumocystis carinii pneumonia. Lancet 1989; 1: 1046-8.
  55. Rolston KV, Hoy J. Role of clindamycin in the treatment of central nervous system toxoplasmosis. Am J Med 1987; 83: 551-4.
  56. Ugwumadu A, Manyonda I, Reid F, Hay P. Effect of early oral clindamycin on late miscarriage and preterm delivery in asymptomatic women with abnormal vaginal flora and bacterial vaginosis: a randomised controlled trial. Lancet 2003; 361: 983-8.
  57. Soper DE. Clindamycin. Obstet Gynecol Clin North Am 1992; 19: 483-96.
  58. Mylonakis E, Ryan ET, Calderwood SB. Clostridium difficile - associated diarrhea: a review. Arch Intern Med 2001; 161: 525-33.
  59. Miller AM, Bassett ML, Dahlstrom JE, Doe WF. Antibiotic-associated haemorrhagic colitis. J Gastroenterol Hepatol 1998; 13: 1115-8.
  60. McFarland LV. Antibiotic-associated diarrhea: epidemiology, trends and treatment. Future Microbiol 2008; 3: 563-78.
  61. Borin MT, Powley GW, Tackwell KR, Batts DH. Absorption of clindamycin after intravaginal application of clindamycin phosphate 2% cream. J Antimicrob Chemother 1995; 35: 833-41.
  62. Lamont RF, Jones BM, Mandal D et al. The efficacy of vaginal clindamycin for the treatment of abnormal genital tract flora in pregnancy. Infect Dis Obstet Gynecol 2003; 11: 181-9.
  63. Lamont RF, Nhan-Chang CL, Sobel JD et al. Treatment of abnormal vaginal flora in early pregnancy with clindamycin for the prevention of spontaneous preterm birth: a systematic review and metaanalysis. Am J Obstet Gynecol 2011; 205 (3): 177-90.
  64. Егорова А.Т., Базина М.И., Рулева М.А. Опыт лечения бактериального вагиноза у беременных женщин клиндацином (крем вагинальный). Рос. вестн. акушера-гинеколога 2010; 6: 68-71.
  65. Шеманаева Т.В., Хосева Е.Н. Нарушения микробиоценоза влагалищной флоры у беременных на разных сроках гестации и особенности их коррекции. Гинекология. 2011; 13 (6): 36-40.
  66. Шеманаева Т.В. Опыт применения свечей клиндацина в лечении беременных с бактериальным вагинозом. Рос. вестн. акушера-гинеколога 2011; 4: 87-9.
  67. Новиков Б.Н., Тец В.В. Клиническая эффективность препарата Клиндацин при лечении бактериального вагиноза у беременных. Рациональная фармакотерапия в акушерстве и гинекологии. Рук. для практикующих врачей. Под общ. ред. В.И.Кулакова, В.Н.Серова. М.: Литтера, 2007; с. 237-40.
  68. Байрамова Г.Р., Прилепская В.Н., Цаллагова Е.В. Оценка эффективности и безопасности применения препарата «Клиндацин» в терапии больных с бактериальным вагинозом. Гинекология. 2006; 8 (5-6): 14-6.

Copyright (c) 2012 Savicheva A.M., Shipitsyna E.V.

Creative Commons License
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies